Clinical Trials Logo
  1. Home
  2. Giant Cell Tumor of Bone
  3. NCT03295981

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Giant Cell Tumor of Bone Clinical Trial

Official title:
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial

Clinical Trial Summary

The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.

Clinical Trial Description

The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate (BP-loaded PMMA bone cement) as a surgical adjuvant can decrease the local recurrence rate of giant cell tumor (GCT) of bone. The investigators will evaluate whether bisphosphonate as a surgical adjuvant improves secondary outcomes, such as pain, function, fever, or wound complications. The hypothesis is that the local administration of bisphosphonate will decrease the recurrence rate of GCT compared to traditional aggressive intralesional curettage. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03295981
Study type Interventional
Source St. Louis University
Contact Allison Gruender, RN
Phone 314-617-3406
Email allison.gruender@health.slu.edu
Status Recruiting
Phase Phase 3
Start date May 3, 2018
Completion date January 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Active, not recruiting NCT04255576 - Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone Phase 1/Phase 2
Completed NCT03301857 - Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Phase 4
Completed NCT05402865 - A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Recruiting NCT03259152 - Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone Phase 3
Recruiting NCT05595603 - Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage Phase 2
Not yet recruiting NCT03358212 - Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China N/A
Completed NCT04002817 - Giant Cell Tumor of the Bone in Young Patients
Completed NCT00396279 - Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone Phase 2
Terminated NCT00889590 - Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) Phase 2
Recruiting NCT04586660 - Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone Phase 4
Active, not recruiting NCT03449108 - LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Phase 2
Not yet recruiting NCT05813665 - A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone Phase 3
Completed NCT02996734 - Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment N/A